March 26, 2021 02:48 PM EDT
Deals
Manufacturing

With $190M in in­vestor cash to play with, Chi­na's Chime Bi­o­log­ics looks to build 15x man­u­fac­tur­ing ca­pac­i­ty by 2024

Josh Sullivan

One year af­ter es­tab­lish­ing it­self as a stand-alone CD­MO, Chime Bi­o­log­ics will start the sec­ond phase of a fa­cil­i­ty ex­pan­sion that plans to in­crease its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Rock­et shares promis­ing long-term re­sults from rare heart dis­ease gene ther­a­py in small study

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

Neu­ro­gene pa­tient had life-threat­en­ing side ef­fect in Rett syn­drome study

No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times